Fact CheckerSign in

NCT07046208Not yet recruiting

Effects os Physiotherapeutic Rehabilitation on Function Autonomic and Inflammatory in Patients With Long Covid

Effects os Physiotherapeutic Rehabilitation on Cardiovascular Autonomic Modulation and Biomarkers Inflammatory and Cardiac Conditions in Patients With Long Covid

Source: ClinicalTrials.gov · Last updated 1 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

Introduction: Long COVID is characterized by persistent symptoms that persist for weeks or months after the acute phase of infection, with a significant impact on the cardiovascular and autonomic systems. Objectives: This study aims to evaluate the effects of a physiotherapeutic rehabilitation protocol on cardiovascular autonomic modulation and on inflammatory and cardiac biomarkers in patients with Long COVID. Methodology: This is a controlled clinical trial, carried out in a cardiorespiratory rehabilitation outpatient clinic, involving individuals with a clinical diagnosis of Long COVID undergoing a protocol of 20 aerobic, anaerobic and respiratory rehabilitation sessions. Heart rate variability (HRV) variables will be analyzed using linear and non-linear methods, in addition to serum levels of CKMB, LDH, ferritin and C-reactive protein. Expected results: Rehabilitation is expected to provide an improvement in autonomic function and a reduction in inflammatory and cardiac markers, contributing to the understanding of the pathophysiological mechanisms of Long COVID and helping to propose evidence-based therapeutic strategies.

Status (registry)
Not yet recruiting
Study type
Interventional
Enrollment
58 (estimated)
First submitted
29 Jun 2025
Start date
11 Aug 2025
Primary completion date
10 Aug 2026
Lead sponsor
Universidade do Estado do Pará
NCT number
NCT07046208

What you commit to

  • Study type: Interventional
  • Planned participants: 58
  • From 11 Aug 2025 to the primary completion date, 10 Aug 2026
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • use of antihypertensive drugs that alter HRV

Other

  • incomplete data.
  • presence of a pacemaker
  • persistent pulmonary alterations
  • persistent desaturation
  • anaemia or presence of reinfection.

Who the study is looking for

  • both sexes
  • aged 20 and 59 years
  • clinical evaluation and undergoing clinical follow-up of Post COVID-19.
  • least one persistent COVID-19-related symptom.

Age in the registry: 20 years to 59 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.